EP0465588A1 - The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions - Google Patents
The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasionsInfo
- Publication number
- EP0465588A1 EP0465588A1 EP19900906472 EP90906472A EP0465588A1 EP 0465588 A1 EP0465588 A1 EP 0465588A1 EP 19900906472 EP19900906472 EP 19900906472 EP 90906472 A EP90906472 A EP 90906472A EP 0465588 A1 EP0465588 A1 EP 0465588A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- liposomes
- cholesterol
- mol
- polymer
- diameter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- This Invention is directed to methods for treating wounds, cuts, and abrasions caused by Injury, trauma, surgery or disease through the delivery of therapeutic healing agents to such sites. More particularly, the Invention is directed to the delivery of therapeutic agents to wounds, cuts and abrasions on the cornea or ocular surface of the eye via l lposome and
- Uposome-polymer compositions which specifically adsorb or adhere to the wound, cut or abrasion.
- Liposomes are sac or vesicle-Hke bllayer structures made of phospholipids.
- Iiposomes as delivery vehicles for drugs or other therapeutic agents.
- Liposomes as delivery vehicles of therapeutic agents to the eye is also known; see for example, U.S. Patent No. 4,649,047 Issued to R. Kaswan, March 10, 1987 disclosing the treatment of traumatic or surgical
- 4,588,578 issued to Fountain et al., May 13, 1986 discloses the preparation of bloactlve agent carrying lipid vesicles which can be applied topically for the treatment of ocular disease such as glaucoma.
- Skuta et al. in American Journal of Ophthalmology, Vol.103, No.5, May, 1987 disclose the delivery of 5-fluorouracil In a Hposome via subconjunctlval Injection as a method for inhibiting flbroblast proliferation following posterior sclerectomles.
- Skuta et al. characterize their delivery system as an advantageous, sustained release delivery system; prior methods of treatment with the free drug required frequent subconjunctlval Injections.
- liposomes for certain types of targeted drug delivery in the,eye has been described previously.
- Norley et al., in J. Immunol., Vol.136, No.2 disclose the targeting of drug-loaded liposomes to Herpes Simplex virus (HSV) Infected comeal cells, in vitro.
- HSV Herpes Simplex virus
- the targeting moiety Incorporated in the liposomes is an antiviral monoclonal antibody to glycoprotem D of HSV containing a covalently-bound fatty acyl chain. This "Immunoliposome" was shown to bind specifically to HSV Infected rabbit comeal cells.
- the sole figure illustrates adsorption of liposomes of the present Invention to corneal wounds versus their relative nonadsorption to unwounded corneas.
- This Invention is directed to methods for treating wounds by the delivery of therapeutic agents in liposomes to the wound site.
- the liposomes preferentially adsorb to wound sites and not to healthy tissue surrounding the sites.
- the Invention is directed to the delivery of therapeutic agents in liposomes to wounds on the surface of the eye, such as the cornea, conjunctiva and sclera. Because the Hposome carriers bioadsorb almost exclusively to the wound site on the ocular surface, the amount of therapeutic agent normally administered as a free agent can be significantly reduced. Consequently, the therapeutic Index or margin of safety of a drug delivered according to the method of this invention will be improved.
- liposomes will preferentially bioadsorb, with a high degree of specificity, to corneal wounds, such as cuts and abrasions.
- the present Invention is based on the surprising discovery that liposomes adhere to wound sites but not to the surrounding healthy tissue.
- wound Includes cuts, scrapes, abrasions or tissue damage caused by Injury, trauma, surgery or disease.
- therapeutic agents which are known to be effective in the treatment of wounds can, according to this Invention, be delivered specifically to wound sites with any nontoxic phosphollpid/cholesterol Hposome.
- the liposomes containing therapeutic agents are useful for treating wounds of the eye, particularly the cornea.
- Liposomes which can be used according to this Invention include any liposoae which bioadsorbs to a wound site,
- liposomes will comprise a llpld and will typically comprise 50-90 mol% of one or more synthetic or naturally occurring phospholiplds and 10-50 molar percent (mol%) cholesterol.
- Phospholiplds which can be used in formulating liposomes for use according to the present invention include: phosphatidylcholine, phosphatldylglycerol, phos ⁇ hatidylethanolamine or phosphatldylserlne with diacyl chains of typically 14 to 18 carbons of either the saturated or monoene variety.
- lipids Including phospholiplds, which can be used in the formllation of the liposomes include, but are not limited to: phosphatidylinositol, sphlngoi ⁇ yeHn, phosphatidic add, cerebrosldes, cardlolipin and Iysophospholipids.
- the liposomes can be prepared by a number of methods, including but not limited to, procedures for preparing
- MLV multilamellar
- SUV small unllamellar
- LUV large unilamellar
- SPLV piurilamellar
- REV reverse-phase evaporation
- liposomes which are relatively small, that is, 10 to 500 nanometers (nm) in diameter, preferably less than 100 nm in diameter exhibit maximal wound site coverage in comparison to the larger MLV-type liposomes of 500 to 10,000 nm in diameter.
- the preferred Uposome composition of the present invention comprises: phosphatldylchollne (50 mol%); the
- the preferred liposomes are 20 to 200 nm in diameter, preferably less than 100 nm.
- the production of liposomes of less than 100 nm is accomplished by passing MLV liposomes through a Microfluldizer R (Microfluidics, Corp., Newton, Mass.) and their size will typically vary less than about 30%.
- the liposomes of the present Invention When composed of phosphatldylchollne with saturated acyl chains, the liposomes of the present Invention have an aqueous liquid-crystalline phase transition of between about 35 and 42 degrees centigrade, preferably close to the human physiological temperature of 37 degrees centigrade.
- the liposomes of the present invention which are composed of phosphatldylchollne with monoene containing acyl chains, exhibit phase transitions well below zero degrees centigrade, and also show good bioadsorptlve properties to wound sites.
- This invention is not limited to only phosphollpld or phospholipid/cholesterol containing liposomes, but also comprises phospholipid/cholesterol liposomes containing polymers.
- These liposome-polymer combinations provide for formulations with increased viscosity. Any polymer which will provide for increased viscosity around the liposomes, and is compatible with the tissues of the eye can be used.
- the polymer(s) are added to provide for a composition with a viscosity of between about 5 cps. and 1000 cps., preferably between about 15 cps. and 200 cps.
- Examples of polymers which can be used according to the methods of this invention Include natural polymers such as
- polysaccharldes e.g. alglnate, starch, modified celluloses such as hydroxypropylmethylcellulose and hydroxyethylcellulose
- gelatins e.g. albumin, casein, chitosan and collagen
- synthetic polymers which can be used include polylactideglycolide copolymer, polylactlde, polyhydroxyethylmethacrylate,
- polyesteramides polyorthoesters, polymethacrylate
- the liposomes in their viscous matrix provide for longer retention of the formulation in the eye and therefore bloadsorptlon of the liposomes to the wound site over longer time periods.
- the percentage of polymer in the Uposome formulation will depend on the polymer Itself, but in general the concentration of polymer can range from about 0.25 - 3.0 wt.%.
- Therapeutic agents which can be delivered to wound sites in uposome or Hposome/polymer formulations which bioadsorb to such sites comprise all therapeutic agents useful for the treatment of wounds, cuts and abrasions caused by Injury, trauma, surgery and/or disease.
- Such therapeutic agents will typically comprise, but are not limited to: growth factors, steroids, antloxldants, nonsteroldal ant1Inflammatory agents, antibiotics, Immunomodulators, antiallerglcs and compounds which make up basement membranes, such as fibronectln and lamlnln.
- Further agents include "biological response modifiers" (I.e. agents whose mechanisms of action Involve the individual's own biological response); see, Oldham, Biological Response Modifiers, Chapter 1, Torrence (Ed.) Academic Press, 1985, Incorporated herein by reference.
- the liposomes containing the therapeutic agent or drug for the treatment of wounds are applied topically to the eye.
- the administration, sequence of administration when more than one therapeutic agent is used, and the concentrations of the therapeutic agents in the liposomes of the present invention depends on numerous factors. These factors can include: the specific therapeutic agent or agents to be used, the nature of the wound, and various clinical factors, Including the extent and type of wound being treated, the medical history of the patient and symptoms associated with the wound, such as Inflammation or edema, etc. Selection of the specific
- the amount and frequency of therapeutic agent normally administered as the free agent can be reduced.
- the amount of therapeutic agent administered in liposomes according to the present invention can be reduced by up to about 2/3 of the dose administered by other methods such as in aqueous drops, ointments or suspensions.
- the following examples are directed to the binding of liposomes and liposomes comprising therapeutic agents to corneal wounds.
- the examples are illustrative of the preferential binding of the liposomes to wound sites, but they are in no way limiting.
- fluorescent dye film was then rehydrated with Dulbecco's phosphate buffered saline containing 0.9 mM calcium and 0.49 mM magnesium (10 ml). The pH was adjusted to 7.4 with dilute sodium hydroxide. This rehydratlon resulted in the spontaneous formation of multilamellar liposomes.
- Freshly dissected rabbit corneas were washed in BSS Plus R (Alcon Laboratories, Inc.). The corneas were placed in plastic culture dishes and either cut or scraped medially through the epithelial surface with a scalpel blade. Immediately following the cutting or scraping, 1 ⁇ 1 of the fluorescentlabeled Uposome formulation was applied to the corneal surface. After 0.5 min the corneas were washed 3 times with 5 ml BSS Plus R at 37°C in a CO 2 Incubator using a rotary shaker.
- Each cornea was examined using fluorescence microscopy by viewing the corneas in a chamber created by two glass
- the flow cell consists of a plastic block (11.5 X 11.5 cm X 1.2 cm) in which four 1 cm holes were bored for viewing under phase.
- a recessed area -2.5 X 2.5 cm and -2.5 mm deep was machined over and around each hole and an 18 X 18 mm coverslip adhered with silicon grease to the block within the recessed area.
- a thin shallow Inset ledge -0.3 mm deep was machined within the 2.5 X 2.5 cm recessed area for accommodating a top coverslip of 25 X 25 mm adhered to the ledge using silicon grease.
- Each wounded cornea was in turn placed on an 18 X 18 mm coverslip in one chamber of the flow cell and covered with a 25 X 25 mm top coverslip.
- the corneas were constantly perfused with BSS Plus R and the temperature was maintained at 37°C
- Video images of the fluorescent-labeled liposomes present on the corneal surface were recorded at a magnification of 1134X.
- the Images appeared black and white with the white regions representing those areas In which the labeled liposomes were located. The black areas in the Images
- liposomes used according to the methods of the present Invention can be used to deliver wound treating agents to wounds because they preferentially adhere to wound sites and not to unwounded sites.
- composition can be applied topically to the eye to promote reepitheliatlon of a wounded cornea.
- EGF Epidermal Growth Factor
- the phospholiplds and cholesterol are weighed as dry lyophilized powders in a glass container (230 mg phosphatldylchollne, 140 mg phosphatldylglycerol, 50 mg cholesterol) followed by the addition of 1 ml t-butanol.
- the mixture is then solubilized by gentle mixing in a 40°C water bath, sterile filtered and then freeze dried to remove the t-butanol.
- the lyophilized llpld powder is then rehydrated with 100 ⁇ g of sterile EGF dissolved in
- Example 3 Dulbecco's phosphate buffered saline containing 0.9 mM calcium and 0.49 mM magnesium (10 ml). This rehydratlon will result in the spontaneous formation of multilamellar liposomes containing EGF. To maximize entrapment of EGF in the liposomes, the formulation is freeze dried a second time then rehydrated with 10ml sterile delonized water before use.
- the phospholiplds and cholesterol are weighed as dry lyophilized powders in a glass container followed by the addition of tertiary-butanol (about 4 ml/4 mg of total lipld).
- Llpophilic drugs and therapeutic agents which are soluble in tertiarybutanol can be added at this point at concentrations effective for the treatment of wounds.
- the mixture is then completely solubllized by gentle mixing in a 40°C water bath and then freeze dried to remove the tertiary-butanol.
- the lyophilized powder is rehydrated with Dulbecco's phosphate buffered saline containing 0.9 mM calcium and 0.49 mH magnesium. The pH is adjusted to 7.4 with dilute sodium hydroxide. Water soluble drugs and
- Multilamellar liposomes containing drugs or therapeutic agents are formed by Incubation and mixing in a rotary water bath at 40°C. For maximum entrapment of water soluble drugs and therapeutic agents, the solution can be freeze dried again and dried again and rehydrated with water followed by further
- the multilamellar liposomes can be passed through a Microfluidizer R (Microfluldlcs, Corp.) repeatedly until the desired proportion of smaller liposomes 1s obtained.
- Microfluidizer R Microfluldlcs, Corp.
- some Uposome formulations for example, some of those containing proteins, should not be passed through the microfluidizer because of denaturation of the protein.
- powdered gelatin (Swine, skin type 1, Sigma Chemical Co., St. Louis, MO.) is added at a concentration of 25 mg/ml formulation. The mixture is then gently heated and mixed at 40°C until the gelatin is solubllized.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Procédés d'apport d'agents thérapeutiques à des blessures par l'intermédiaire de liposomes qui se fixent de préférence sur les blessures. Sont également décrits des procédés d'apport d'agents thérapeutiques contenus dans des liposomes à des blessures sur la surface oculaire de l'oeil.Methods of delivering therapeutic agents to wounds via liposomes which preferably attach to wounds. Also disclosed are methods of delivering therapeutic agents contained in liposomes to wounds on the ocular surface of the eye.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33316489A | 1989-04-04 | 1989-04-04 | |
US333164 | 1989-04-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0465588A1 true EP0465588A1 (en) | 1992-01-15 |
EP0465588A4 EP0465588A4 (en) | 1992-06-03 |
Family
ID=23301595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19900906472 Withdrawn EP0465588A4 (en) | 1989-04-04 | 1990-04-03 | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0465588A4 (en) |
JP (1) | JPH04505319A (en) |
KR (1) | KR920700691A (en) |
AU (1) | AU633078B2 (en) |
CA (1) | CA2013770A1 (en) |
IL (1) | IL93996A0 (en) |
WO (1) | WO1990011781A1 (en) |
ZA (1) | ZA902593B (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05503527A (en) * | 1990-02-22 | 1993-06-10 | マクノート・ピーティーワイ・リミテッド | artificial tears |
IT1240683B (en) * | 1990-04-26 | 1993-12-17 | Zambon Spa | PHARMACEUTICAL COMPOSITION CONTAINING EGF |
DE9312509U1 (en) * | 1993-08-20 | 1993-10-28 | Euro-Celtique S.A., Luxemburg/Luxembourg | Preparations for external administration of antiseptic and / or wound healing promoting agents |
US5863556A (en) * | 1993-08-20 | 1999-01-26 | Euro-Celtique, S.A. | Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds |
US5589189A (en) * | 1994-09-14 | 1996-12-31 | Nexstar Pharmaceuticals, Inc. | Liposome dispersion |
JP3058920B2 (en) * | 1996-04-19 | 2000-07-04 | 一男 坪田 | Pharmaceutical composition containing albumin as an active ingredient |
EP0982025A1 (en) * | 1998-08-28 | 2000-03-01 | Wilhelm Prof. Dr. Stoffel | Synthetic tear fluid |
RU2264827C2 (en) | 1999-05-27 | 2005-11-27 | Еуро-Селтик С.А. | Preparations for removing antiphlogistic agents |
US7300667B1 (en) | 1999-05-27 | 2007-11-27 | Euro-Celtique, S.A. | Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract |
US7297344B1 (en) | 1999-05-27 | 2007-11-20 | Euro-Celtique, S.A. | Preparations for the promotion of wound healing in the upper respiratory tract and/or ear |
GB9919131D0 (en) * | 1999-08-14 | 1999-10-13 | Depuy Int Ltd | Joint lubrication |
WO2002074281A1 (en) * | 2001-03-15 | 2002-09-26 | Novartis Ag | Ophthalmic compositions and use thereof |
IL159119A0 (en) * | 2001-06-15 | 2004-05-12 | Cornerstone Pharmaceuticals | Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
DE10141018A1 (en) * | 2001-08-22 | 2003-03-13 | Eth Zuerich Eidgenoessische Te | Use of negatively charged phospholipids and compositions comprising phospholipids for the treatment of the eye |
DK1427394T3 (en) * | 2001-09-18 | 2007-06-11 | Vasogen Ireland Ltd | Process for Accelerating Recovery from Trauma Using Apoptosis-Imitating Synthetic or Natural Devices |
HK1077740A1 (en) | 2001-12-20 | 2006-02-24 | Ct Ingenieria Genetica Biotech | Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation |
NZ534142A (en) * | 2002-01-21 | 2007-08-31 | Vasogen Ireland Ltd | Pharmaceutically acceptable phosphate-glycerol carrying bodies comprising phospatidylglycerol and/or phosphatidylcholine and/or phosphatidylglycerol |
CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
WO2004024123A1 (en) * | 2002-09-16 | 2004-03-25 | Vasogen Ireland Limited | Accelerating recovery from trauma |
AU2003275850A1 (en) * | 2002-10-25 | 2004-05-13 | Vasogen Ireland Limited | Cyclooxygenase regulation with ps liposomes |
AU2003275842A1 (en) * | 2002-10-25 | 2004-05-13 | Vasogen Ireland Limited | Cyclooxygenase regulation with pg liposomes |
WO2004082688A1 (en) * | 2003-03-20 | 2004-09-30 | Vasogen Ireland Limited | Phosphatidylglycerol (pg) receptor agonists and antagonists |
JP4669665B2 (en) * | 2004-04-12 | 2011-04-13 | 正彦 阿部 | Polycation-modified liposome having no cytotoxicity and method for producing the same |
US8808715B1 (en) * | 2004-11-23 | 2014-08-19 | Georgia Regents Research Institute, Inc | Methods and compositions for modulating keratinocyte function |
WO2007038549A1 (en) * | 2005-09-26 | 2007-04-05 | Vasogen Ireland Limited | Treatment of inflammation and vascular abnormalities of the eye |
CU23411B6 (en) * | 2005-12-29 | 2009-09-08 | Ct Ingenieria Genetica Biotech | TOPICAL USE OF THE EPIDERMAL GROWTH FACTOR IN LIPOSOMAS TO PREVENT AMBUTATION OF THE DIABETIC FOOT |
CU23388B6 (en) | 2006-01-31 | 2009-07-16 | Ct Ingenieria Genetica Biotech | PHARMACEUTICAL COMPOSITION OF MICROSPHERES TO PREVENT AMPUTATION OF THE DIABETIC FOOT |
ES2284398B2 (en) * | 2006-04-27 | 2008-12-16 | Universidad Complutense De Madrid | FORMULATION OF LIPOSOMAL VESICLES IN WATER SOLUTIONS WITH CHARACTERISTICS OF LAGRIMAL FILM. |
KR100752990B1 (en) | 2006-08-02 | 2007-08-30 | 주식회사 대웅 | Compositions for preventing or treating skin diseases comprising nanoliposomes and natural extracts |
CN101959503A (en) | 2008-02-29 | 2011-01-26 | 财团法人名古屋产业科学研究所 | Oculi posterior segment arrives with liposome and oculi posterior segment disease medical composition |
WO2009118658A2 (en) * | 2008-03-26 | 2009-10-01 | University Of Oxford | Endoplasmic reticulum targeting liposomes |
EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
EP2410989A2 (en) | 2009-03-27 | 2012-02-01 | The Chancellor, Masters and Scholars of the University of Oxford | Cholesterol level lowering liposomes |
US11052158B2 (en) * | 2016-08-18 | 2021-07-06 | Troy Bremer | Delivery of urea to cells of the macula and retina using liposome constructs |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2540381A1 (en) * | 1983-02-08 | 1984-08-10 | Dior Sa Parfums Christian | METHOD FOR STIMULATING GROWTH OF CELLS; COSMETIC, PHARMACEUTICAL COMPOSITION AND COMPLEMENTARY COMPOSITION FOR CELL CULTURE MEDIA APPLYING SAID METHOD |
WO1988000824A1 (en) * | 1986-07-28 | 1988-02-11 | Liposome Technology, Inc. | Liposomes with enhanced retention on mucosal tissue |
WO1990009782A1 (en) * | 1989-02-24 | 1990-09-07 | Liposome Technology, Inc. | Liposome gel composition and method |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4708861A (en) * | 1984-02-15 | 1987-11-24 | The Liposome Company, Inc. | Liposome-gel compositions |
US4692454A (en) * | 1986-02-03 | 1987-09-08 | Warner-Lambert Company | Opthalmic use of quinolone antibiotics |
US4839175A (en) * | 1986-07-28 | 1989-06-13 | Liposome Technology, Inc. | Liposomes with enhanced retention on mucosal tissue |
US4752425A (en) * | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
-
1990
- 1990-04-03 WO PCT/US1990/001664 patent/WO1990011781A1/en not_active Application Discontinuation
- 1990-04-03 AU AU54297/90A patent/AU633078B2/en not_active Expired - Fee Related
- 1990-04-03 CA CA002013770A patent/CA2013770A1/en not_active Abandoned
- 1990-04-03 IL IL93996A patent/IL93996A0/en unknown
- 1990-04-03 KR KR1019910701279A patent/KR920700691A/en not_active Application Discontinuation
- 1990-04-03 EP EP19900906472 patent/EP0465588A4/en not_active Withdrawn
- 1990-04-03 JP JP2506117A patent/JPH04505319A/en active Pending
- 1990-04-04 ZA ZA902593A patent/ZA902593B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2540381A1 (en) * | 1983-02-08 | 1984-08-10 | Dior Sa Parfums Christian | METHOD FOR STIMULATING GROWTH OF CELLS; COSMETIC, PHARMACEUTICAL COMPOSITION AND COMPLEMENTARY COMPOSITION FOR CELL CULTURE MEDIA APPLYING SAID METHOD |
WO1988000824A1 (en) * | 1986-07-28 | 1988-02-11 | Liposome Technology, Inc. | Liposomes with enhanced retention on mucosal tissue |
WO1990009782A1 (en) * | 1989-02-24 | 1990-09-07 | Liposome Technology, Inc. | Liposome gel composition and method |
Non-Patent Citations (1)
Title |
---|
See also references of WO9011781A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2013770A1 (en) | 1990-10-04 |
WO1990011781A1 (en) | 1990-10-18 |
JPH04505319A (en) | 1992-09-17 |
ZA902593B (en) | 1991-01-30 |
AU5429790A (en) | 1990-11-05 |
AU633078B2 (en) | 1993-01-21 |
EP0465588A4 (en) | 1992-06-03 |
KR920700691A (en) | 1992-08-10 |
IL93996A0 (en) | 1991-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU633078B2 (en) | The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions | |
US20240058269A1 (en) | Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same | |
US4755388A (en) | Liposome-encapsulated 5-fluoropyrimidines and methods for their use | |
US5221696A (en) | Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs | |
EP0790823B1 (en) | Drug releasing surgical implant or dressing material | |
RU2443412C2 (en) | Dried reconstituted vesicles for pharmaceutical application | |
EP0225130A2 (en) | Liposome composition | |
US20020048596A1 (en) | Preparation for the transport of an active substance across barriers | |
Ramadan et al. | Development and investigation of timolol maleate niosomal formulations for the treatment of glaucoma | |
JPH0822814B2 (en) | Biodegradable eye implant | |
JP2001503396A (en) | Therapeutic liposome compositions and methods | |
US11129900B2 (en) | Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion | |
KR100446832B1 (en) | Liquid droplets for the manufacture of a preparation for the non-invasive application or for the non-invasive transport of active ingredients through barriers | |
AU2017313907B2 (en) | Delivery of urea to cells of the macula and retina using liposome constructs | |
EP0443809A2 (en) | Coated intraocular lens and coatings therefor | |
KR20090115856A (en) | Pharmaceutical composition comprising a campothecin derivative | |
Kondo et al. | Iontophoresis of 5-fluorouracil into the conjunctiva and sclera. | |
US20220265556A1 (en) | Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament | |
Heath et al. | Antiproliferative and anticontractile effects of liposome encapsulated fluoroorotate. | |
ITMI20060556A1 (en) | INTERACTIVE MEDICATIONS FOR THE CARE OF DERMATOLOGICAL DISEASES | |
Tilleul et al. | Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits | |
RU2339369C2 (en) | Tratment for ocular disorders, using urea and its derivatives | |
EP2590666B1 (en) | Topical application of erythropoietin for use in the treatment of injuries of the cornea | |
Niesman et al. | Liposome uptake by human retinal pigment epithelial cells in culture | |
US20030236246A1 (en) | Method for decreasing capillary permeability in the retina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19911022 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SHAW, JACK, MICHAEL Inventor name: CORDOVA, DIANA, MARIA |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19920413 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19930416 |